Skip to main content

26 September 2011

Smiths Medical, a division of the global technology business Smiths Group plc, today announced its new Medfusion® 4000 wireless syringe pump and associated software had gained clearance from the U.S. Food and Drug Administration (FDA).

The customizable system, which includes the PharmGuard® software suite, allows health care providers to send and receive medication delivery information more efficiently. Eliminating the need to locate and manually update pumps can significantly help reduce the chance of medication errors.

Smiths Medical President Srini Seshadri said: "This next-generation model of the popular Medfusion® series, which has already been well received in Canada and other countries, demonstrates our ability to develop advanced delivery products that meet a specific clinical demand. Receiving FDA clearance to launch it in the biggest healthcare market in the world is obviously a major breakthrough."

Medfusion® 4000 enables hospitals to capture a wide range of infusion data which PharmGuard® transfers into simple, accessible information for evidence-based practice improvements. As the number of drugs on backorder increases, a wireless system to update drug libraries on pumps improves both patient safety and clinical care by allowing quick and easy updates.

Related articles


Smiths Interconnect launches new technology to reduce power loss in industrial batteries

Innovative, environmentally friendly product provides up to 90% more energy transfer than existing offering

Find out more Call to action arrow icon
Alister Cowan

Smiths Group Appoints Alister Cowan as Non-Executive Director

Find out more Call to action arrow icon
Earth View

Smiths Group plc – Q3 Trading Update

Find out more Call to action arrow icon
Sign up for updates Call to action arrow icon